080d03cb-01ea-4dc7-af41-12e3f3877283
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 80
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.290
- E2F_TARGETS+0.280
- MYC_TARGETS_V2+0.250
- G2M_CHECKPOINT+0.240
- FATTY_ACID_METABOLISM+0.220
- MTORC1_SIGNALING+0.210
- MYC_TARGETS_V1+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.200
- PEROXISOME+0.150
- PI3K_AKT_MTOR_SIGNALING+0.110
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.640
- TGF_BETA_SIGNALING-0.470
- ANGIOGENESIS-0.460
- COAGULATION-0.410
- UV_RESPONSE_DN-0.410
- APICAL_SURFACE-0.400
- INFLAMMATORY_RESPONSE-0.390
- IL6_JAK_STAT3_SIGNALING-0.360
- MYOGENESIS-0.340
- INTERFERON_GAMMA_RESPONSE-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 64935b9c-623d-40d4-bd89-f2af006b1f92 | — | — | 0.916 |
| 2 | SRR1797243 | — | cohortSC | 0.908 |
| 3 | a8ce7460-8ccd-4638-a854-55c4068af6ec | — | — | 0.898 |
| 4 | SRR12475110 | — | — | 0.897 |
| 5 | TCGA-51-4080-01A-01R-1100-07 | — | cohortSQ2 | 0.892 |
| 6 | TCGA-A8-A06Q-01A-11R-A034-07 | — | C | 0.891 |
| 7 | TCGA-85-8070-01A-11R-2247-07 | — | cohortSQ2 | 0.888 |
| 8 | cabd9320-506a-4695-a18a-7c8602633f90 | — | — | 0.888 |
| 9 | TCGA-73-A9RS-01A-11R-A41B-07 | — | cohortA4 | 0.886 |
| 10 | AUR-AFR3-TTM1-A-1-1-R-A743-41 | — | C | 0.885 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.280 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.250 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.210 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.110 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.080 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.050 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.040 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.010 | Inavolisib | — uncovered |